Thematics Asset Management Acquires 6,963 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Thematics Asset Management increased its holdings in Thermo Fisher Scientific by 15.9%, owning a total of 50,799 shares after purchasing an additional 6,963 shares, making it the fund's 24th largest investment.
• Executives from Thermo Fisher, including CEO Marc N. Casper, recently sold shares, collectively totaling nearly $4.7 million, which indicates a minor reduction in their ownership stakes.
• The company has a current market capitalization of $188.90 billion and reported earnings per share of $5.36 for the most recent quarter, exceeding analysts' expectations.

Thematics Asset Management grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 15.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,799 shares of the medical research company's stock after purchasing an additional 6,963 shares during the period. Thermo Fisher Scientific makes up approximately 1.3% of Thematics Asset Management's investment portfolio, making the stock its 24th biggest position. Thematics Asset Management's holdings in Thermo Fisher Scientific were worth $25,278,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Apexium Financial LP lifted its holdings in shares of Thermo Fisher Scientific by 11.3% in the 1st quarter. Apexium Financial LP now owns 895 shares of the medical research company's stock valued at $446,000 after acquiring an additional 91 shares during the last quarter. ICONIQ Capital LLC lifted its holdings in shares of Thermo Fisher Scientific by 137.4% in the 1st quarter. ICONIQ Capital LLC now owns 1,595 shares of the medical research company's stock valued at $794,000 after acquiring an additional 923 shares during the last quarter. Oliver Luxxe Assets LLC lifted its holdings in shares of Thermo Fisher Scientific by 9.7% in the 1st quarter. Oliver Luxxe Assets LLC now owns 9,767 shares of the medical research company's stock valued at $4,860,000 after acquiring an additional 861 shares during the last quarter. Jump Financial LLC lifted its holdings in shares of Thermo Fisher Scientific by 48.2% in the 1st quarter. Jump Financial LLC now owns 72,654 shares of the medical research company's stock valued at $36,153,000 after acquiring an additional 23,643 shares during the last quarter. Finally, APG Asset Management N.V. lifted its holdings in shares of Thermo Fisher Scientific by 3.7% in the 1st quarter. APG Asset Management N.V. now owns 382,196 shares of the medical research company's stock valued at $176,061,000 after acquiring an additional 13,806 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. William Blair began coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a report on Friday, July 11th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Finally, Barclays increased their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,896 shares of company stock valued at $13,603,438 in the last three months. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 0.0%

Shares of NYSE TMO traded down $0.01 during trading hours on Wednesday, reaching $488.47. The stock had a trading volume of 1,294,754 shares, compared to its average volume of 2,075,498. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market cap of $184.45 billion, a price-to-earnings ratio of 28.25, a P/E/G ratio of 2.61 and a beta of 0.74. The business's fifty day moving average price is $446.71 and its two-hundred day moving average price is $455.47. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.